Bhanvi Satija | Reuters
Jan 7, 2025 · Bhanvi Satija reports on pharmaceutical companies and the healthcare industry in the United States. She has a postgraduate degree in International Journalism from City, …
Bhanvi Satija - Sector Specialist - Reuters | LinkedIn
View Bhanvi Satija’s profile on LinkedIn, a professional community of 1 billion members. She/Her. Covering U.S. Health & Pharma at Reuters · A multimedia journalist who is passionate...
- Title: She/Her. Covering U.S. Health …
- Location: Reuters
- 500+ connections
E-sellers of compounded weight-loss drugs fail to reveal risks
By Bhanvi Satija and Christy Santhosh (Reuters) -Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do not …
Bhanvi Satija’s Profile | Reuters Journalist - Muck Rack
Find Bhanvi Satija of Reuters's articles, email address, contact information, Twitter and more
J&J doubles down on neurological drugs with $14.6 billion Intra ...
4 days ago · Bhanvi Satija reports on pharmaceutical companies and the healthcare industry in the United States. She has a postgraduate degree in International Journalism from City, …
UnitedHealth Group CEO says complex US healthcare system …
2 days ago · By Sriparna Roy and Bhanvi Satija (Reuters) -UnitedHealth CEO Andrew Witty said on Thursday that healthcare in the U.S. needs to be "less confusing, less complex and less …
US hospitals see post pandemic catch-up behind insurer …
Feb 13, 2024 · Bhanvi Satija reports on pharmaceutical companies and the healthcare industry in the United States. She has a postgraduate degree in International Journalism from City, …
Articles by Bhanvi Satija’s Profile - Muck Rack
Dec 6, 2024 · Articles by Bhanvi Satija on Muck Rack. Find Bhanvi Satija's email address, contact information, LinkedIn, Twitter, other social media and more.
J&J doubles down on neurological drugs with $14.6 billion Intra
By Bhanvi Satija and Puyaan Singh (Reuters) -Johnson & Johnson said on Monday it would buy neurological drugmaker Intra-Cellular Therapies for $14.6 billion, its biggest deal in more than …
Lilly shares on track for worst day since 2021 after downbeat …
3 days ago · By Bhanvi Satija and Patrick Wingrove (Reuters) -Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street …